Sylvain Rheims Selected Research

Partial Epilepsies (Epilepsy, Partial)

1/2022	Functional connectivity and epileptogenicity of nodular heterotopias: A single-pulse stimulation study.
1/2022	Coffee consumption and seizure frequency in patients with drug-resistant focal epilepsy.
12/2021	Neuromodulation in epilepsy: state-of-the-art approved therapies.
1/2021	Relation between coffee consumption and risk of seizure-related respiratory dysfunction in patients with drug-resistant focal epilepsy.
1/2021	Clinical Management of Drug Resistant Epilepsy: A Review on Current Strategies.
1/2019	Hypoxemia following generalized convulsive seizures: Risk factors and effect of oxygen therapy.
12/2018	Effective accuracy of stereoelectroencephalography: robotic 3D versus Talairach orthogonal approaches.
12/2018	Stereo-electroencephalography-guided radiofrequency thermocoagulation in patients with focal epilepsy: A systematic review and meta-analysis.
10/2018	European trends in epilepsy surgery.
3/2018	[Management of drug-resistant epilepsy].

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sylvain Rheims Research Topics

Disease

30	Epilepsy (Aura) 09/2022 - 08/2008
24	Partial Epilepsies (Epilepsy, Partial) 01/2022 - 08/2008
23	Seizures (Absence Seizure) 09/2022 - 04/2006
7	Drug Resistant Epilepsy 09/2022 - 05/2010
6	Temporal Lobe Epilepsy 07/2020 - 08/2011
4	Sudden Unexpected Death in Epilepsy 01/2019 - 11/2011
3	Tuberous Sclerosis (Bourneville's Disease) 01/2022 - 01/2020
3	Hypoxia (Hypoxemia) 01/2021 - 11/2016
3	Autoimmune Diseases of the Nervous System 01/2021 - 05/2018
3	Epileptic Syndromes 01/2016 - 01/2008
2	Glioma (Gliomas) 09/2022 - 10/2014
2	Status Epilepticus (Complex Partial Status Epilepticus) 01/2022 - 12/2021
2	Generalized Epilepsy 06/2021 - 07/2014
2	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2021 - 01/2016
2	Apnea 01/2021 - 11/2016
2	Frontal Lobe Epilepsy (Epilepsy, Supplementary Motor) 08/2019 - 04/2006
2	Intellectual Disability (Idiocy) 07/2019 - 01/2006
2	Encephalitis (Encephalitis, Rasmussen) 05/2018 - 05/2012
2	Neoplasms (Cancer) 10/2014 - 12/2013
2	Brain Neoplasms (Brain Tumor) 10/2014 - 07/2011
2	Autosomal Dominant Nocturnal Frontal Lobe Epilepsy 04/2006 - 01/2006
1	Limbic Encephalitis (Paraneoplastic Limbic Encephalitis) 09/2022
1	Atrophy 09/2022
1	Spasm (Spasms) 01/2022
1	Malformations of Cortical Development 01/2022
1	Intracranial Hypertension 12/2021
1	Progressive Myoclonic Epilepsies (Progressive Myoclonic Epilepsy) 01/2021
1	Myoclonic Epilepsies (Myoclonic Encephalopathy) 01/2021
1	Infantile Spasms (West Syndrome) 01/2021
1	Cognitive Dysfunction 05/2018
1	Mental Disorders (Mental Disorder) 05/2018
1	Infections 03/2017
1	Hematoma 03/2017
1	Pneumocephalus 03/2017
1	Pain (Aches) 11/2016
1	Coma (Comas) 11/2016
1	Hippocampal Sclerosis 02/2016
1	Anxiety Disorders (Anxiety Disorder) 09/2015
1	Cerebral Infarction 06/2015
1	Ischemic Stroke 06/2015
1	Stroke (Strokes) 06/2015
1	Infarction (Infarctions) 06/2015
1	Neuroepithelial Neoplasms (Gliomatosis Cerebri) 10/2014
1	Ganglioglioma 10/2014
1	Sturge-Weber Syndrome (Sturge-Kalischer-Weber Syndrome) 08/2009

Drug/Important Bio-Agent (IBA)

28	Pharmaceutical PreparationsIBA 09/2022 - 04/2006
19	Anticonvulsants (Antiepileptic Drugs)IBA 01/2019 - 01/2008
3	trans-sodium crocetinate (crocetin)IBA 01/2022 - 01/2020
3	gamma-Aminobutyric Acid (GABA)IBA 08/2009 - 08/2008
2	Coffee FDA Link 01/2022 - 01/2021
2	Biomarkers (Surrogate Marker)IBA 06/2021 - 01/2019
2	Methylphenidate (Ritalin)FDA LinkGeneric 01/2021 - 01/2016
2	AntibodiesIBA 07/2020 - 05/2012
2	AutoantibodiesIBA 01/2019 - 05/2018
2	perampanelIBA 01/2018 - 01/2013
1	Leucine (L-Leucine)FDA Link 09/2022
1	anti-leucine-rich glioma-inactivated 1 autoantibodyIBA 09/2022
1	Pilocarpine (Ocusert)FDA LinkGeneric 01/2022
1	Serotonin (5 Hydroxytryptamine)IBA 01/2022
1	Tryptophan HydroxylaseIBA 01/2022
1	Thiopental (Pentothal)FDA Link 12/2021
1	Purinergic P1 Receptors (Adenosine Receptor)IBA 01/2021
1	Everolimus FDA Link 01/2021
1	Caffeine (No Doz)FDA LinkGeneric 01/2021
1	CatecholaminesIBA 01/2021
1	Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA 07/2020
1	eslicarbazepine acetateIBA 07/2019
1	Oxygen (Dioxygen)IBA 01/2019
1	AntigensIBA 01/2019
1	N-Methylaspartate (NMDA)IBA 05/2018
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 05/2018
1	Naltrexone (ReVia)FDA LinkGeneric 11/2016
1	Narcotic Antagonists (Opioid Antagonists)IBA 11/2016
1	Opioid Analgesics (Opioids)IBA 11/2016
1	Naloxone (Narcan)FDA LinkGeneric 11/2016
1	Dihydrotachysterol (AT 10)IBA 02/2016
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 06/2015
1	GadoliniumIBA 10/2014
1	Methionine (L-Methionine)FDA Link 10/2014
1	2,6-dinitrotoluene (DNT)IBA 10/2014
1	Valproic Acid (Depakote)FDA LinkGeneric 07/2014
1	ezogabine (retigabine)IBA 05/2012
1	Amyloid beta-PeptidesIBA 03/2009
1	Lamotrigine (Lamictal)FDA LinkGeneric 02/2009
1	Pregabalin (Lyrica)FDA Link 12/2008

Therapy/Procedure

11	Therapeutics 12/2021 - 12/2008
6	Electrodes (Electrode) 01/2022 - 12/2008
3	Anterior Temporal Lobectomy 09/2018 - 02/2016
2	Precision Medicine 02/2021 - 01/2019
2	Electrocoagulation (Electrocautery) 12/2018 - 01/2017
1	Deep Brain Stimulation 12/2021
1	Vagus Nerve Stimulation 12/2021
1	Activities of Daily Living (ADL) 11/2021
1	Craniotomy 04/2021
1	Transition to Adult Care 01/2019
1	Oral Administration 11/2016
1	Intravenous Injections 11/2016
1	Thrombolytic Therapy 06/2015
1	Drug Therapy (Chemotherapy) 07/2014
1	Radiotherapy 07/2011